Search clinical trials for: BNT162b5 Bivalent (Original/OMI BA.4/BA.5)

Total 20 results

BioNTech SE
Pfizer

Completed

A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals

COVID-19 | SARS-CoV-2 Infection

United States
BioNTech SE
Pfizer

Withdrawn

A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children

COVID-19
Pfizer

Completed

A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

Healthy Participants

United States
BioNTech SE
Pfizer

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza

COVID-19 | Influenza, Human

United States
BioNTech SE
Pfizer

Active, not recruiting

Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People

COVID-19 | SARS-CoV-2 Infection

United States
BioNTech SE
Pfizer

Recruiting

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

COVID-19 | Severe Acute Respiratory Syndrome Coronavirus 2 | SARS-CoV-2 Virus

United States, South Africa, Brazil, Puerto Rico
Jules Bordet Institute
Roche Pharma AG

Terminated

COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2 (I-SPARC)

Cancer

Belgium
Catholic Kwandong University
Korea University Guro Hospital

Completed

Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines

Immune Response | Safety

Korea, Republic of
National Institute of Allergy and Infectious Diseases...

Completed

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

COVID-19

United States
ModernaTX, Inc.

Recruiting

Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT and SPIKEVAX X Injection.

SARS-CoV-2

Korea, Republic of
Pfizer

Recruiting

Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California

COVID-19

United States
Novavax

Completed

Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines (COVID-19)

COVID-19 | SARS CoV 2 Infection

Australia
Bayside Health
Monash University

Recruiting

Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

Lymphoma, Non-Hodgkin | Multiple Myeloma | HIV | Chronic Lymphocytic Leukemia | Organ Transplantation | COVID-19 Vaccines

Australia
Assistance Publique - Hôpitaux de Paris
IREIVAC/COVIREIVAC Network

Active, not recruiting

Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine (CoviBOOST 2)

COVID-19 | Vaccine Reaction

France
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Hunan Provincial Center for Disease Control and Prevention

Not yet recruiting

Omicron BA.4/5-Delta COVID-19 Vaccine Phase I Clinical Trial

COVID-19
WestVac Biopharma Co., Ltd.

Not yet recruiting

A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination

COVID-19
Zhongnan Hospital
Institute of Biotechnology, Academy of Military Medical Sciences, PLA of...

Recruiting

A Clinical Trial on Booster Immunization of Two COVID-19 Vaccines Constructed From Different Technical Routes

COVID-19

China
Novavax

Active, not recruiting

Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines (COVID-19)

COVID-19

United States
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Not yet recruiting

Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)

Coronavirus
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Completed

Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)

Coronavirus

China

3

Subscribe